Known chiefly for its leadership in the generics space, India’s vast pharmaceutical market is one of the largest in the world by both volume, for which it is ranked third, and value, where it comes in at tenth. As the supplier of around 40% of generic demand in the United States and over 50% of global demand for various vaccines, the country has been aptly dubbed “the pharmacy of the world” for its critical role in supplying life saving medications to both developed and developing nations at affordable prices. While its prowess as an international pharmaceutical hub is hardly in question, India will face significant challenges in the years to come as the global industry modernizes and the renaissance in biopharmaceuticals and innovative therapies continue to alter the life sciences. As the 2020 milestone approaches, the question must be asked: how far has India come in achieving its government-led Pharma 2020 Vision to address these challenges? GBR sets out to answer this question in our latest IE publication, and following months of on-the-ground research, our field team encountered conflicting narratives across India’s three key pharmaceutical clusters: Mumbai, Hyderabad and Gujarat.